Composition of Herantis Pharma Plc's Shareholders' Nomination Committee
Herantis Pharma Plc, Company release, 15 November 2021 at 5:00 p.m. EET
The following members have been appointed to Herantis Pharma's Shareholders' Nomination Committee:
- Marko Berg, Helsinki University Funds (HYR) (Chairman),
- Pia Gisgard, Swedbank Robur,
- Aki Prihti, Inveni Life Sciences Fund I Ky, and
- Timo Veromaa, the Chairman of Herantis Pharma's Board of Directors.
Herantis Pharma's Shareholders' Nomination Committee consists of four members, of which three represent the company's shareholders. The Chairman of Herantis Pharma's Board of Directors will serve as the fourth member of the Nomination Committee.
The Shareholders' Nomination Committee prepares and presents to the Annual General Meeting proposals on the remuneration, number and members of the Board of Directors.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
---------------------------------
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis focuses on disease modifying therapies for debilitating neurodegenerative diseases by restoring the neuronal protective mechanism of proteostasis, a key system in neurodegenerative disease. Proteostasis regulates proteins within the body and influences the fate of every protein from synthesis to degradation. Its failure results in a vicious cycle of pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated with the development of many neurodegenerative diseases including Parkinson’s Disease, Alzheimer’s and other diseases. rhCDNF (a biological protein) is Herantis’ lead program and a clinical stage asset; and HER-096 (a synthetic peptide version of CDNF) is Herantis’ follow-on program. CDNF is a natural protein that occurs naturally in the body whose natural role is to protect neurons by balancing and supporting proteostasis, thereby preventing and counteracting disease generating mechanisms. Herantis is taking this natural ability and harnessing it as a treatment for neurodegenerative disease. Both rhCDNF and HER-096, via their multimodal mechanism of action, have the potential to improve neuronal survival and stop the progression of Parkinson’s and other neurodegenerative diseases with a significant therapeutic impact on the quality of patients’ lives.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, please visit www.herantis.com/